Molecular Therapeutics Unit

GBM
Patient-derived primary GBM cells stained with DAPI (blue) and α-tubulin for immunofluorescence microscopy

The foundation for the development of effective cancer therapeutics depends on hypothesis-driven basic science research and its translation to clinical endeavors. Glioblastoma (GBM) is the most common malignant primary brain tumor. It remains incurable despite aggressive, multimodal therapy and has proven to be an enduring challenge. In the Molecular & Therapeutics Unit, we extensively study the pathophysiology of GBM in the context of potential therapeutic candidates using preclinical in vivo and in vitro GBM models.

Our lab has three major goals:

  1. Identify and validate novel therapeutic targets for GBM.
  2. Develop biological and/or small molecule agents to target the validated therapeutic candidates.
  3. Drug repurposing.